Sixfold Bioscience Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 18

Sixfold Bioscience General Information

Description

Developer of a ribonucleic acid delivery platform designed to conduct cell and gene therapeutics. The company's platform utilizes nanoparticles to simultaneously deliver therapeutic, diagnostic and targeting molecules to diseased cells such as cancer cells, even those in the most inaccessible regions of the body, such as the brain, enabling medical professionals to offer treatment to their patients.

Contact Information

Website
www.sixfold.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Imperial College White City Incubator
  • Translation And Innovation Hub
  • London W12 0BZ
  • England, United Kingdom
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Biotechnology
Corporate Office
  • The Imperial College White City Incubator
  • Translation And Innovation Hub
  • London W12 0BZ
  • England, United Kingdom

Sixfold Bioscience Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sixfold Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Accelerator/Incubator 01-Sep-2023 Completed Pre-Clinical Trials
11. Grant 01-Mar-2023 Completed Pre-Clinical Trials
10. Accelerator/Incubator 19-Jan-2022 Completed Pre-Clinical Trials
9. Secondary Transaction - Private Completed Pre-Clinical Trials
8. Seed Round 02-Dec-2021 Completed Pre-Clinical Trials
7. Grant 01-Sep-2021 Completed Pre-Clinical Trials
6. Grant 01-Apr-2021 Completed Pre-Clinical Trials
5. Grant 01-Mar-2020 Completed Pre-Clinical Trials
4. Grant 01-Oct-2019 $80.4K $120K Completed Pre-Clinical Trials
3. Seed Round 01-Jan-2019 $120K Completed Pre-Clinical Trials
To view Sixfold Bioscience’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Sixfold Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a ribonucleic acid delivery platform designed to conduct cell and gene therapeutics. The company's platform
Drug Delivery
London, United Kingdom
8 As of 2025

Baltimore, MD
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sixfold Bioscience Competitors (50)

One of Sixfold Bioscience’s 50 competitors is WindMIL Therapeutics, a Venture Capital-Backed company based in Baltimore, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
WindMIL Therapeutics Venture Capital-Backed Baltimore, MD
Akari Therapeutics Formerly VC-backed London, United Kingdom
Carmine Therapeutics Venture Capital-Backed Cambridge, MA
Regenxbio Formerly VC-backed Rockville, MD
Triumvira Venture Capital-Backed Hamilton, Canada
You’re viewing 5 of 50 competitors. Get the full list »

Sixfold Bioscience Patents

Sixfold Bioscience Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026057749-A1 Method and product Pending 11-Sep-2024
EP-4594520-A2 Compositions containing oligonucleotides with theranostic applications Pending 30-Sep-2022
US-20260201363-A1 Compositions containing oligonucleotides with theranostic applications Pending 30-Sep-2022
WO-2024069235-A2 Compositions containing oligonucleotides with theranostic applications Inactive 30-Sep-2022
WO-2024069235-A3 Compositions containing oligonucleotides with theranostic applications Inactive 30-Sep-2022 C12Q1/6816
To view Sixfold Bioscience’s complete patent history, request access »

Sixfold Bioscience Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sixfold Bioscience Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Grow London Accelerator/Incubator
Biomedical Catalyst Government
Coalition for Epidemic Preparedness Innovations Impact Investing Minority
Wellcome Leap Not-For-Profit Venture Capital Minority
Cantos Ventures Venture Capital Minority
You’re viewing 5 of 18 investors. Get the full list »

Sixfold Bioscience FAQs

  • When was Sixfold Bioscience founded?

    Sixfold Bioscience was founded in 2017.

  • Where is Sixfold Bioscience headquartered?

    Sixfold Bioscience is headquartered in London, United Kingdom.

  • What is the size of Sixfold Bioscience?

    Sixfold Bioscience has 8 total employees.

  • What industry is Sixfold Bioscience in?

    Sixfold Bioscience’s primary industry is Drug Delivery.

  • Is Sixfold Bioscience a private or public company?

    Sixfold Bioscience is a Private company.

  • What is Sixfold Bioscience’s current revenue?

    The current revenue for Sixfold Bioscience is .

  • How much funding has Sixfold Bioscience raised over time?

    Sixfold Bioscience has raised $10.6M.

  • Who are Sixfold Bioscience’s investors?

    Grow London, Biomedical Catalyst, Coalition for Epidemic Preparedness Innovations, Wellcome Leap, and Cantos Ventures are 5 of 18 investors who have invested in Sixfold Bioscience.

  • Who are Sixfold Bioscience’s competitors?

    WindMIL Therapeutics, Akari Therapeutics, Carmine Therapeutics, Regenxbio, and Triumvira are some of the 50 competitors of Sixfold Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process